| Literature DB >> 29559953 |
Dillon F Da Fonte1, Chris J Martyniuk2, Lei Xing1, Vance L Trudeau1.
Abstract
Radial glial cells (RGCs) are the main macroglia in the teleost brain and have established roles in neurogenesis and neurosteroidogenesis. They are the only brain cell type expressing aromatase B (cyp19a1b), the enzyme that synthesizes estrogens from androgen precursors. There are few studies on the regulation of RGC functions, but our previous investigations demonstrated that dopamine stimulates cyp19a1b expression in goldfish RGCs, while secretoneurin A (SNa) inhibits the expression of this enzyme. Here, we determine the range of proteins and cellular processes responsive to SNa treatments in these steroidogenic cells. The focus here is on SNa, because this peptide is derived from selective processing of secretogranin II in magnocellular cells embedded within the RGC-rich preoptic nucleus. Primary cultures of RGCs were treated (24 h) with 10, 100, or 1,000 nM SNa. By using isobaric tagging for relative and absolute quantitation and a Hybrid Quadrupole Obritrap Mass Spectrometry system, a total of 1,363 unique proteins were identified in RGCs, and 609 proteins were significantly regulated by SNa at one or more concentrations. Proteins that showed differential expression with all three concentrations of SNa included H1 histone, glutamyl-prolyl-tRNA synthetase, Rho GDP dissociation inhibitor γ, vimentin A2, and small nuclear ribonucleoprotein-associated protein. At 10, 100, and 1,000 nM SNa, there were 5, 195, and 489 proteins that were downregulated, respectively, whereas the number of upregulated proteins were 72, 44, and 51, respectively. Subnetwork enrichment analysis of differentially regulated proteins revealed that processes such as actin organization, cytoskeleton organization and biogenesis, apoptosis, mRNA processing, RNA splicing, translation, cell growth, and proliferation are regulated by SNa based on the proteomic response. Moreover, we observed that, at the low concentration of SNa, there was an increase in the abundance of proteins involved in cell growth, proliferation, and migration, whereas higher concentration of SNa appeared to downregulate proteins involved in these processes, indicating a dose-dependent proteome response. At the highest concentration of SNa, proteins linked to the etiology of diseases of the central nervous system (brain injuries, Alzheimer disease, Parkinson's disease, cerebral infraction, brain ischemia) were also differentially regulated. These data implicate SNa in the control of cell proliferation and neurogenesis.Entities:
Keywords: aromatase; neurogenesis; radial glial cells; secretogranin II; secretoneurin
Year: 2018 PMID: 29559953 PMCID: PMC5845582 DOI: 10.3389/fendo.2018.00068
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Figure 1Gene ontology classification of Carassius auratus radial glial cell (RGC) proteins into molecular function, biological function, and cellular component categories. The number of proteins ascribed to each classification, along with accession number, is provided.
Figure 2Gene ontology classification of Carassius auratus radial glial cell (RGC) proteins by protein class. The number of proteins ascribed to each classification, along with accession number, is provided.
Top 25 pathway ontologies associated with Carassius auratus RGC proteins based on number of protein identified in each pathway.
| Pathway name | Pathway accession | # of proteins identified |
|---|---|---|
| Parkinson disease | P00049 | 31 |
| Integrin signaling pathway | P00034 | 28 |
| Ubiquitin proteasome pathway | P00060 | 26 |
| Cytoskeletal regulation by Rho GTPase | P00016 | 26 |
| Huntington disease | P00029 | 25 |
| Inflammation mediated by chemokine and cytokine signaling pathway | P00031 | 24 |
| FGF signaling pathway | P00021 | 15 |
| EGF receptor signaling pathway | P00018 | 15 |
| CCKR signaling map | P06959 | 14 |
| Wnt signaling pathway | P00057 | 14 |
| Angiogenesis | P00005 | 13 |
| Gonadotropin-releasing hormone receptor pathway | P06664 | 12 |
| Cadherin signaling pathway | P00012 | 12 |
| Alzheimer disease-presenilin pathway | P00004 | 10 |
| T cell activation | P00053 | 10 |
| Nicotinic acetylcholine receptor signaling pathway | P00044 | 10 |
| Ras pathway | P04393 | 10 |
| Glycolysis | P00024 | 10 |
| Cell cycle | P00013 | 10 |
| Apoptosis signaling pathway | P00006 | 8 |
| TGF-beta signaling pathway | P00052 | 7 |
| P02738 | 7 | |
| PDGF signaling pathway | P00047 | 7 |
| Dopamine receptor-mediated signaling pathway | P05912 | 7 |
| Axon guidance mediated by Slit/Robo | P00008 | 6 |
.
Figure 3Volcano plots for protein expression in Carassius auratus radial glial cells (RGCs) treated with three concentrations of secretoneurin A. Significantly regulated proteins were determined using a cut off of >1.5 or <0.5 and P < 0.05. Red and green dots represent proteins that are upregulated and downregulated, respectively.
Expression patterns of the differentially regulated proteins in Carassius auratus RGCs treated with various concentrations of SNa compared to control.
| Expression pattern | 10 nM | 100 nM | 1000 nM | Number of protein IDs |
|---|---|---|---|---|
| I | ↑ | ↑ | ↑ | 5 |
| II | ↑ | ↑ | – | 9 |
| III | ↑ | – | ↑ | 3 |
| IV | ↑ | – | – | 31 |
| V | ↑ | – | ↓ | 20 |
| VI | ↑ | ↓ | ↓ | 4 |
| VII | – | ↑ | ↑ | 11 |
| VIII | – | ↑ | – | 18 |
| IX | – | ↑ | ↓ | 1 |
| X | – | – | ↑ | 25 |
| XI | – | – | – | 757 |
| XII | – | – | ↓ | 288 |
| XIII | – | ↓ | ↑ | 6 |
| XIV | – | ↓ | – | 7 |
| XV | – | ↓ | ↓ | 176 |
| XVI | ↓ | – | – | 3 |
| XVII | ↓ | ↓ | ↑ | 1 |
| XVIII | ↓ | ↓ | – | 1 |
RGC, radial glial cell.
Figure 4Venn diagram showing the overlap of differentially expressed proteins following secretoneurin A (10–1,000 nM) treatment in Carassius auratus radial glial cells.
Top 20 proteins identified by iTRAQ as different in abundance among groups in Carassius auratus RGCs treated with one of three concentrations of SNa.
| Concentration (nM) | Accession | Protein | % coverage protein ID | Fold change | |
|---|---|---|---|---|---|
| 10 | A7MCL7_DANRE | Cystatin 14a, tandem duplicate 2 | 47 | 3.34 | 2.02E−07 |
| Q6DN21_CARAU | Calmodulin long form | 99.33 | 5.94 | 6.11E−06 | |
| A0A0C5Q0E9_MEGAM | Fibroblast growth factor receptor 1b | 11.62 | 1.54 | 7.76E−06 | |
| E7F1X7_DANRE | Serine and arginine repetitive matrix 1 | 33.69 | 1.65 | 8.06E−06 | |
| VIM2_CARAU | Vimentin A2 | 44.03 | 3.72 | 8.07E−06 | |
| F1QNJ3_DANRE | Testin LIM domain protein | 25.51 | 4.29 | 8.58E−06 | |
| F1Q5X0_DANRE | Synaptosome associated protein 29 kDa | 44.74 | 4.29 | 9.73E−06 | |
| B0UXN7_DANRE | C-Abl oncogene 2, non-receptor tyrosine kinase | 20.18 | 3.00 | 1.19E−05 | |
| C0LYZ3_9TELE | High-mobility group box 1 | 55.44 | 2.02 | 1.23E−05 | |
| A0A0R4IMX7_DANRE | SH3 and PX domains 2B | 25.68 | 1.87 | 1.23E−05 | |
| X1WGZ7_DANRE | Glutamyl-prolyl-tRNA synthetase | 25.03 | 4.57 | 1.25E−05 | |
| E7F354_DANRE | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase | 57.89 | 3.03 | 1.25E−05 | |
| Q802W6_DANRE | Arhgdia protein | 39.41 | 2.70 | 2.01E−05 | |
| Q6Y3R4_CARAU | H1 histone | 34.03 | 4.66 | 2.43E−05 | |
| B3DGP9_DANRE | Protein tyrosine kinase 2aa | 11.29 | 1.58 | 3.44E−05 | |
| Q6NYA1_DANRE | Heterogeneous nuclear ribonucleoprotein A/Bb | 36.25 | 7.30 | 3.53E−05 | |
| Q802Y1_DANRE | Serine/arginine-rich splicing factor 4 | 39.34 | 1.57 | 4.18E−05 | |
| 143BA_DANRE | Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta | 77.46 | 0.15 | 6.06E−05 | |
| RBM8A_DANRE | RNA-binding protein 8A | 22.99 | 1.90 | 6.22E−05 | |
| F1QG80_DANRE | Ribosomal protein L22 | 34.75 | 1.60 | 7.03E−05 | |
| 100 | Q5U7N6_DANRE | Talin 1 | 18.95 | 0.45 | 9.82E−07 |
| Q4U0S2_DANRE | Myosin, heavy chain 11a, smooth muscle | 24.77 | 0.49 | 3.08E−06 | |
| E7FEK9_DANRE | Golgin A4 | 40.17 | 0.04 | 4.72E−06 | |
| F1QIN6_DANRE | CAP-GLY domain containing linker protein 2 | 43.21 | 0.05 | 4.76E−06 | |
| Q1LXT2_DANRE | Eukaryotic translation elongation factor 2a, tandem duplicate 1 | 26.11 | 1.60 | 5.96E−06 | |
| F1QTN7_DANRE | Acidic leucine-rich nuclear phosphoprotein 32 family member A | 27.38 | 0.13 | 7.51E−06 | |
| E7EYW2_DANRE | Epsin 2 | 16.27 | 0.02 | 8.56E−06 | |
| Q7ZW39_DANRE | Phosphoribosyl pyrophosphate synthetase 1A | 22.33 | 0.08 | 9.34E−06 | |
| F1R1J9_DANRE | AHNAK nucleoprotein | 53.03 | 2.60 | 1.08E−05 | |
| Q502F6_DANRE | Zgc:112271 protein | 75.58 | 0.29 | 1.20E−05 | |
| EIF3L_DANRE | Eukaryotic translation initiation factor 3 subunit L | 22.57 | 0.28 | 1.30E−05 | |
| C0LYZ3_9TELE | High-mobility group box 1 | 55.44 | 1.57 | 1.35E−05 | |
| Q7ZU46_DANRE | Heat shock protein 4a | 28.45 | 0.14 | 1.36E−05 | |
| Q0PWB8_DANRE | PDZ and LIM domain 3b | 32.7 | 0.11 | 1.51E−05 | |
| Q9DF20_DANRE | Fragile X mental retardation 1 | 40.77 | 0.10 | 1.51E−05 | |
| A4FUN5_DANRE | ISY1 splicing factor homolog | 57.54 | 0.32 | 1.75E−05 | |
| Q1LYC9_DANRE | Calpain, small subunit 1 a | 47.69 | 0.35 | 2.04E−05 | |
| Q6DRC1_DANRE | Small nuclear ribonucleoprotein F | 48.84 | 0.17 | 2.90E−05 | |
| F1QYM4_DANRE | Eukaryotic translation initiation factor 4 h | 55.08 | 0.50 | 3.11E−05 | |
| F1Q7S0_DANRE | Vesicle transport through interaction with t-SNAREs 1A | 41.94 | 0.03 | 3.32E−05 | |
| 1,000 | Q5U7N6_DANRE | Talin 1 | 18.95 | 0.11 | 3.56E−09 |
| A0JMJ1_DANRE | Scinderin like a | 33.06 | 0.03 | 4.60E−07 | |
| Q0GC55_CARAU | Heat shock protein 47 kDa | 24.81 | 0.34 | 7.06E−07 | |
| Q6PBR5_DANRE | ATPase, H+ transporting, V1 subunit G isoform 1 | 80.51 | 3.05 | 7.17E−07 | |
| F1RDG4_DANRE | si:dkey-222f2.1 | 55.02 | 0.28 | 7.79E−07 | |
| Q7ZTZ6_DANRE | STIP1 homology and U-Box containing protein 1 | 34.51 | 0.02 | 8.19E−07 | |
| F1R1J9_DANRE | AHNAK nucleoprotein | 53.03 | 2.86 | 8.48E−07 | |
| Q804W1_DANRE | Parvalbumin isoform 4b | 45.87 | 0.01 | 1.22E−06 | |
| F1QFN1_DANRE | ELKS/RAB6-interacting/CAST family member 1b | 31.20 | 0.19 | 1.41E−06 | |
| EIF3L_DANRE | Eukaryotic translation initiation factor 3 subunit L | 22.57 | 0.10 | 1.42E−06 | |
| Q7SXA1_DANRE | Ribosomal protein L26 | 55.17 | 0.03 | 1.63E−06 | |
| E7F049_DANRE | Kinectin 1 | 26.47 | 0.20 | 1.90E−06 | |
| Q7ZW39_DANRE | Phosphoribosyl pyrophosphate synthetase 1A | 22.33 | 0.03 | 1.96E−06 | |
| Q803A9_DANRE | DnaJ (Hsp40) homolog, subfamily B, member 11 | 11.94 | 0.38 | 2.32E−06 | |
| A0A0R4I9C6_DANRE | Ubiquitin-fold modifier 1 | 73.33 | 0.35 | 2.55E−06 | |
| B8JJS6_DANRE | Programmed cell death protein 10-B | 32.86 | 9.51 | 2.58E−06 | |
| F1QTN7_DANRE | Acidic leucine-rich nuclear phosphoprotein 32 family member A | 27.38 | 0.04 | 2.58E−06 | |
| A4FUN5_DANRE | ISY1 splicing factor homolog | 57.54 | 0.11 | 2.59E−06 | |
| Q502F6_DANRE | zgc:112271 | 75.58 | 0.12 | 2.74E−06 | |
| Q9W792_DANRE | T-complex polypeptide 1 | 26.98 | 0.05 | 2.78E−06 | |
All fold changes are relative to control.
iTRAQ, isobaric tagging for relative and absolute quantitation; RGC, Radial glial cell; SNa, secretoneurin A.
Figure 5Cellular processes of blood vessel development, actin organization, cytoskeleton organization and biogenesis, cell proliferation, growth, and migration were enriched in primary Carassius auratus radial glial cell culture after 10 nM secretoneurin A treatment (P < 0.05) based on the protein profiles. Red indicates that the protein is increased, and green indicates that the protein is decreased in abundance relative to the control group. All abbreviations are provided in Table S4 in Supplementary Material.
Figure 6Cellular processes of actin organization, cell proliferation, and growth were significantly enriched in primary Carassius auratus radial glial cell culture after 100 nM secretoneurin A treatment (P < 0.05) based on the protein profiles. Red indicates that the protein is increased, and green indicates that the protein is decreased in abundance relative to the control group. All abbreviations are provided in Table S4 in Supplementary Material.
Figure 7Cellular processes of (A) neurite outgrowth and nerve fiber regeneration and (B) tight and gap junction assembly were enriched in primary Carassius auratus radial glial cell culture after 1,000 nM secretoneurin A treatment (P < 0.05) based on the protein profiles. Red indicates that the protein is increased, and green indicates that the protein is decreased in abundance relative to the control group. All abbreviations are provided in Table S4 in Supplementary Material.
Figure 8Alzheimer, Parkinson, and neurodegenerative disease pathways were enriched in primary Carassius auratus radial glial cell culture after 1,000 nM secretoneurin A treatment (P < 0.05) based on the protein profiles. Red indicates that the protein is increased, and green indicates that the protein is decreased in abundance relative to the control group. All abbreviations are provided in Table S4 in Supplementary Material.